vs
Side-by-side financial comparison of PARK AEROSPACE CORP (PKE) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $17.3M, roughly 1.1× PARK AEROSPACE CORP). SCYNEXIS INC runs the higher net margin — 65.7% vs 17.0%, a 48.7% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 20.3%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 3.0%).
Park Electrochemical Corp, now called the Park Aerospace Corp, is a Melville, New York-based materials manufacturer for the telecommunications, Internet infrastructure, high-end computing, and aerospace industries. It produces high-technology digital and radio frequency(RF)/microwave printed circuit material products, composite materials. Its printed circuit materials are used for complex multilayer printed circuit boards and other electronic interconnection systems, such as multilayer back-p...
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
PKE vs SCYX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.3M | $18.6M |
| Net Profit | $3.0M | $12.3M |
| Gross Margin | 34.1% | — |
| Operating Margin | 21.0% | 56.3% |
| Net Margin | 17.0% | 65.7% |
| Revenue YoY | 20.3% | 1808.5% |
| Net Profit YoY | 87.1% | 376.5% |
| EPS (diluted) | $0.15 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.3M | $18.6M | ||
| Q3 25 | $16.4M | $334.0K | ||
| Q2 25 | $15.4M | $1.4M | ||
| Q1 25 | $16.9M | $257.0K | ||
| Q4 24 | $14.4M | $977.0K | ||
| Q3 24 | $16.7M | $660.0K | ||
| Q2 24 | $14.0M | $736.0K | ||
| Q1 24 | $16.3M | $1.4M |
| Q4 25 | $3.0M | $12.3M | ||
| Q3 25 | $2.4M | $-8.6M | ||
| Q2 25 | $2.1M | $-6.9M | ||
| Q1 25 | $1.2M | $-5.4M | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $2.1M | $-2.8M | ||
| Q2 24 | $993.0K | $-14.5M | ||
| Q1 24 | $2.7M | $411.0K |
| Q4 25 | 34.1% | — | ||
| Q3 25 | 31.2% | — | ||
| Q2 25 | 30.6% | — | ||
| Q1 25 | 29.3% | — | ||
| Q4 24 | 26.6% | — | ||
| Q3 24 | 28.5% | — | ||
| Q2 24 | 29.3% | — | ||
| Q1 24 | 27.3% | — |
| Q4 25 | 21.0% | 56.3% | ||
| Q3 25 | 17.4% | -2516.5% | ||
| Q2 25 | 15.7% | -701.0% | ||
| Q1 25 | 16.8% | -3350.2% | ||
| Q4 24 | 12.8% | — | ||
| Q3 24 | 15.7% | -1563.6% | ||
| Q2 24 | 14.9% | -1255.0% | ||
| Q1 24 | 15.7% | -692.5% |
| Q4 25 | 17.0% | 65.7% | ||
| Q3 25 | 14.7% | -2572.2% | ||
| Q2 25 | 13.5% | -504.8% | ||
| Q1 25 | 7.4% | -2097.7% | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 12.4% | -425.5% | ||
| Q2 24 | 7.1% | -1964.4% | ||
| Q1 24 | 16.3% | 29.9% |
| Q4 25 | $0.15 | $0.25 | ||
| Q3 25 | $0.12 | $-0.17 | ||
| Q2 25 | $0.10 | $-0.14 | ||
| Q1 25 | $0.06 | $-0.11 | ||
| Q4 24 | $0.08 | — | ||
| Q3 24 | $0.10 | $-0.06 | ||
| Q2 24 | $0.05 | $-0.30 | ||
| Q1 24 | $0.13 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.6M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $106.6M | $49.4M |
| Total Assets | $118.1M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.6M | $40.0M | ||
| Q3 25 | $61.6M | $37.9M | ||
| Q2 25 | $65.6M | $44.8M | ||
| Q1 25 | $68.8M | $40.6M | ||
| Q4 24 | $70.0M | $59.3M | ||
| Q3 24 | $72.0M | $68.8M | ||
| Q2 24 | $74.4M | $73.0M | ||
| Q1 24 | $77.2M | $80.2M |
| Q4 25 | $106.6M | $49.4M | ||
| Q3 25 | $105.8M | $36.4M | ||
| Q2 25 | $105.0M | $44.5M | ||
| Q1 25 | $107.2M | $50.5M | ||
| Q4 24 | $107.4M | $55.1M | ||
| Q3 24 | $110.3M | $58.5M | ||
| Q2 24 | $111.7M | $60.4M | ||
| Q1 24 | $112.9M | $74.1M |
| Q4 25 | $118.1M | $59.0M | ||
| Q3 25 | $116.4M | $51.1M | ||
| Q2 25 | $120.7M | $60.7M | ||
| Q1 25 | $122.1M | $67.9M | ||
| Q4 24 | $124.2M | $90.6M | ||
| Q3 24 | $125.1M | $99.0M | ||
| Q2 24 | $129.4M | $107.8M | ||
| Q1 24 | $132.3M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.1M | $18.4M |
| Free Cash FlowOCF − Capex | $4.3M | — |
| FCF MarginFCF / Revenue | 24.6% | — |
| Capex IntensityCapex / Revenue | 4.8% | — |
| Cash ConversionOCF / Net Profit | 1.73× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $3.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | $18.4M | ||
| Q3 25 | $-2.1M | $-8.7M | ||
| Q2 25 | $1.6M | $-7.5M | ||
| Q1 25 | $969.0K | $-7.5M | ||
| Q4 24 | $2.7M | $-24.0M | ||
| Q3 24 | $1.4M | $765.0K | ||
| Q2 24 | $-423.0K | $-10.9M | ||
| Q1 24 | $5.3M | $-4.0M |
| Q4 25 | $4.3M | — | ||
| Q3 25 | $-2.3M | — | ||
| Q2 25 | $1.1M | — | ||
| Q1 25 | $338.0K | — | ||
| Q4 24 | $2.7M | — | ||
| Q3 24 | $1.3M | — | ||
| Q2 24 | $-435.0K | — | ||
| Q1 24 | $5.1M | — |
| Q4 25 | 24.6% | — | ||
| Q3 25 | -14.0% | — | ||
| Q2 25 | 7.2% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 18.6% | — | ||
| Q3 24 | 7.5% | — | ||
| Q2 24 | -3.1% | — | ||
| Q1 24 | 31.4% | — |
| Q4 25 | 4.8% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 3.7% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 1.0% | — |
| Q4 25 | 1.73× | 1.50× | ||
| Q3 25 | -0.88× | — | ||
| Q2 25 | 0.76× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 1.73× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | -0.43× | — | ||
| Q1 24 | 1.98× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PKE
| North America | $16.8M | 97% |
| Other | $546.0K | 3% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
